Show simple item record

Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains

dc.contributor.authorGeorgiev, Ivelin S.
dc.identifier.citationAndrew D Redd, Nicole A Doria-Rose, Joshua A Weiner, Martha Nason, Matthew Seivers, Stephen D Schmidt, Oliver Laeyendecker, Craig Martens, Daniel Bruno, Brandon F Keele, Nagarajan Raju, Ivelin S Georgiev, Susanna L Lamers, Jacquie Astemborski, Gregory D Kirk, John R Mascola, Margaret E Ackerman, Shruti H Mehta, Thomas C Quinn, Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains, The Journal of Infectious Diseases, Volume 221, Issue 5, 1 March 2020, Pages 756–765,
dc.identifier.issneISSN: 1537-6613
dc.descriptionOnly Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at
dc.description.abstractBackground. Multiple factors influence the human immunodeficiency virus (HIV) antibody response produced during natural infection, leading to responses that can vary in specificity, strength, and breadth. Methods. People who inject drugs identified as recently infected with HIV (n = 23) were analyzed for clustering of their viral sequences (genetic distance, <2%). Longitudinal antibody responses were identified for neutralizing antibody (Nab) potential, and differences in antibody subclass, specificity, and Fc receptor ligation using pseudovirus entry and multiplexed Fc array assays, respectively. Responses were analyzed for differences between subject groups, defined by similarity in the sequence of the infecting virus. Results. Viral sequences from infected individuals were grouped into 3 distinct clusters with 7 unclustered individuals. Subjects in cluster 1 generally had lower antibody response magnitudes, except for antibodies targeting the V1/V2 region. Subjects in clusters 2 and 3 typically had higher antibody response magnitudes, with the Fv specificity of cluster 2 favoring gp140 recognition. NAb responses differed significantly between clusters for 3 of 18 pseudoviruses examined (P < .05), but there were no differences in overall NAb breadth (P = .62). Discussion. These data demonstrate that individuals infected with similar viral strains can generate partially similar antibody responses, but these do not drastically differ from those in individuals infected with relatively unrelated strains.en_US
dc.description.sponsorshipThis work was supported by the Collaboration for AIDS Vaccine Discovery Antigen Reagent Program; the Division of Intramural Research and Vaccine Research Center, National Institute of Allergy and Infectious Diseases and National Institute of General Medical Sciences; the National Cancer Institute, NIH (contract HHSN261200800 National Heart Lung and Blood Institute 001E); and the NIH (grants R01 AI131975, R01 DA036297, R01 AI131722, and R01 DA12568).en_US
dc.publisherJournal of Infectious Diseasesen_US
dc.rightsThis article is a work of the United States government. Such works are not entitled to domestic copyright protection under U.S. law and are therefore in the public domain. This act only applies to U.S. domestic copyright as that is the extent of U.S. federal law. The U.S. government asserts that it can still hold the copyright to those works in other countries
dc.subjectneutralizing antibodyen_US
dc.subjectantibody developmenten_US
dc.subjectpeople who inject drugsen_US
dc.subjectcluster linkageen_US
dc.titleLongitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strainsen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record